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Objectives. This study was undertaken to test the hypothesis
that lipoprotein(a) [Lp(a)] impairs endothelial function.
Background. Elevated Lp(a) plasma levels have been demon-
strated to be associated with an increased risk of coronary heart
disease. In atherosclerosis, endothelial dysfunction is known to be
an early indicator of vascular changes. However, the effect of
Lp(a) on nitric oxide (NO)-dependent vasodilator response has
not yet been determined. We therefore examined the influence of
Lp(a) on basal and stimulated NO-mediated vasodilator response
in the forearm vascular bed.
Methods. Strain gauge plethysmography was used to measure
changes in forearm blood flow produced by intraarterial infusion
of increasing doses of acetylcholine (3, 12, 24 and 48 mg/min),
sodium nitroprusside (200, 800 and 3,200 ng/min) and
N-monomethyl L-arginine (L-NMMA) (1, 2 and 4 mmol/min) in 57
white subjects (mean age 6 SD 37 6 14 years). Lp(a) plasma
concentrations were determined by rocket immunoelectrophore-
sis.
Results. Endothelium-dependent vasodilation tested by intraar-
terial acetylcholine and endothelium-independent vascular relax-
ation tested by intraarterial sodium nitroprusside were not cor-
related with Lp(a). Similarly, no significant differences in forearm
blood flow changes were observed when patients were classified
into tertiles according to their individual Lp(a) concentration. In
contrast, changes in forearm blood flow after intraarterial
L-NMMA indicating basal production and release of NO differed
significantly among tertiles. Patients in the highest Lp(a) tertile
(49.2 6 20.3 mg/dl) had a much greater vasoconstrictive response
to L-NMMA than patients in the lowest Lp(a) tertile (4.8 6
2.5 mg/dl): 2 mmol/min of L-NMMA, 223.6 6 22.5% vs. 210.4 6
9.1% (p < 0.02); 4 mmol/min of L-NMMA, 227.8 6 10.3% vs.
217.6 6 9.9% (p < 0.03). Lp(a) plasma level consistently corre-
lated negatively with the forearm blood flow responses to 4
mmol/min of intraarterial L-NMMA (r 5 20.38, p < 0.01).
Multiple stepwise regression analysis of variables, including total
and high and low density lipoprotein cholesterol, further con-
firmed that plasma Lp(a) remained a significant independent
determinant of forearm blood flow changes in response to
L-NMMA (p < 0.02).
Conclusions. The endothelium-dependent vasoconstrictive re-
sponse to L-NMMA was enhanced in subjects with relatively high
Lp(a) plasma levels, suggesting an increased basal production
and release of NO. This response seemed to reflect a compensa-
tory mechanism of the endothelium to yet unknown Lp(a)-induced
atherosclerotic effects.
(J Am Coll Cardiol 1998;31:359–65)
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In previous prospective studies (1–4), elevated lipoprotein(a)
[Lp(a)] plasma levels have been shown to predict cardiovascu-
lar disease. In addition to established cardiovascular risk
factors, elevated serum levels of Lp(a) indicate an increased
risk for major coronary events (5). Well recognized atheroscle-
rotic risk factors such as smoking, high blood pressure, diabe-
tes mellitus and hypercholesterolemia, are known (6–9) to
impair endothelium-dependent vasodilation, even if no clinical
or angiographic signs of atherosclerosis are present. For
example, elevated low density lipoprotein (LDL) cholesterol
levels attenuated the vasodilator response to acetylcholine in
coronary arteries that appeared normal on coronary angio-
grams (6,10). Furthermore, elevated high density lipoprotein
(HDL) levels were shown (11) to ameliorate abnormal vaso-
constriction in early atherosclerosis. Similar interactions were
demonstrated between Lp(a) levels and cerebrovascular dis-
ease (12,13). An elevated Lp(a) plasma level in hypercholes-
terolemic patients was found to be an independent risk factor
for thickening of common carotid arteries (14), which in turn is
associated with an increased risk of cerebrovascular events.
Although Lp(a) concentration is mainly genetically deter-
mined, it was suggested that plasma concentrations might be
altered by conditions such as renal disease (15), liver disease
(16), age, gender, body mass index and hemostatic factors (17).
Controversially, other investigators (18) did not find any
relation between Lp(a) and other well known cardiovascular
risk factors. It is also poorly defined which Lp(a) concentration
represents the threshold for the development of atherosclero-
sis and associated conditions. Most previous studies (1–5)
reported that the atherogenetic threshold of plasma Lp(a)
levels in humans is between 20 and 30 mg/dl.
The exact pathogenetic mechanism by which elevated Lp(a)
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plasma levels contribute to the development of atherosclerosis
is not completely understood. Experimental studies (19) sug-
gest that some components of Lp(a) can enhance lipid depo-
sition in vessel walls, thereby interfering with fibrinolysis,
smooth muscle cell activity and endothelial function. In vivo
studies (6,20,21) revealed increasing evidence that endothe-
lium dysfunction assessed by administration of endothelium-
dependent vasoactive substances, such as acetylcholine and
N-monomethyl L-arginine (L-NMMA), may precede and pro-
mote the process of atherosclerosis in humans. Therefore, the
assessment of endothelial function is helpful in detecting
stages of early vascular structural changes, even before athero-
sclerotic lesions of the coronary arteries can be angiographi-
cally detected.
To our knowledge, there have been no reports on the effect
of elevated Lp(a) plasma levels on endothelium function in the
human vasculature. We therefore conducted this study in
middle-aged white subjects to test the hypothesis that elevated
Lp(a) plasma levels considered as an independent risk factor
for atherosclerosis impair endothelium function. We assessed
vasoreactive response to endothelium-dependent (acetylcho-
line, L-NMMA) and endothelium-independent (sodium nitro-
prusside) vasoactive substances. In a first approach we used the
human forearm vasculature because of its easy accessibility,
lack of adverse and potentially lethal complications (as ob-
served in the coronary arteries) and its close relation to other
human vasculature, as reported earlier (22).
Methods
Study cohort. According to a program for the prevention
of cardiovascular disease initiated by the University of
Erlangen-Nuremberg, ;400 white male and female persons
from the area of Nuremberg were screened for hypercholes-
terolemia and asked to participate in a scientific study regard-
less of their cholesterol level. If they agreed to participate,
subjects were consecutively enrolled and asked to refer to our
outpatient clinic of the Department of Medicine, University of
Erlangen-Nuremberg. A total of 57 middle-aged white subjects
(33 male and 24 female, mean age 6 SD 37 6 14 years)
fulfilled all inclusion criteria such as no clinical evidence of
atherosclerosis or any cardiovascular disease. No participant
followed any lipid-lowering dietary guideline, was receiving
antilipemic therapy or had diabetes or secondary hyperlipid-
emia. A routine clinical evaluation and a 12-lead electrocar-
diogram performed in all subjects yielded no evidence of
pathologic findings. The study protocol was approved by the
ethics committee of the University of Erlangen-Nuremberg
and all participants gave written informed consent before the
study.
Study protocol. Throughout the study period, subjects
rested in a supine position in a quiet room with a controlled
temperature of 22°C. An intraarterial line was inserted under
strict aseptic conditions into the brachial artery of the left arm
with use of the Seldinger technique. After brachial cannula-
tion, patients rested for 30 min before the study was begun.
The forearm vascular response to vasoactive agents was as-
sessed by venous occlusion plethysmography with a sealed
alloy-filled, double-stranded strain gauge (EC 5R Plethysmo-
graph). Hand blood flow was excluded by means of a wrist cuff
inflated to 200 mm Hg during the measurement phase. Venous
occlusion pressure on the arm was 50 mm Hg. Drugs were
infused at a rate of 2 ml/min by an infusion pump. Three
substances were administered. To assess endothelium-
dependent vasodilation, intraarterial acetylcholine was infused
at sequential doses of 3, 12, 24 and 48 mg/min. Sodium
nitroprusside was administered intraarterially (at doses of 200,
800 and 3,200 ng/min) to test endothelium-independent va-
sorelaxation and L-NMMA was administered at doses of 1, 2
and 4 mmol/min to test the basal production and release of
nitric oxide. Each dose was infused for 5 min. Before each
intervention with a different drug, forearm blood flow was
allowed to return to rest levels for 15 min. Baseline forearm
blood flow was obtained from an average of three measure-
ments. Forearm blood flow responses were measured at the
end of each infusion period as the average of three consecutive
steady state measurements. No significant changes in blood
pressure or heart rate were observed during drug administra-
tion, thus verifying the local application of each drug and
excluding systemic effects of the vasoactive substances.
Measurements of Lp(a) and other lipids. Plasma Lp(a)
levels were determined by using a commercially available
rocket immunoelectrophoresis (Immuno AG, Vienna). Apoli-
poproteins A and B were measured by nephelometry (Behring,
Marburg). Total cholesterol, triglycerides and high density
lipoprotein (HDL) cholesterol were measured by an enzymatic
technique according to the specifications of the Lipid Research
Clinics Program (23). LDL cholesterol was calculated by the
formula of Friedewald et al. (24).
Statistical analysis. Vascular reactivity data are expressed
as the percent change from the corresponding baseline values.
Patients were arbitrarily classified into tertiles according to
their Lp(a) plasma concentration. Analysis of variance
(ANOVA) with the Bonferroni correction was applied to test
differences among tertiles. Linear regression analysis was used
to evaluate the effect of Lp(a) and other variables on forearm
blood flow changes. Multiple stepwise regression analysis was
then conducted to analyze which of the univariate variables
were independent determinants of the vasoreactive response
to the different drugs infused. The variable with the highest
partial correlation was entered at each step until no variable
remained with an F value $2. Changes in forearm blood flow
Abbreviations and Acronyms
ANOVA 5 analysis of variance
HDL 5 high density lipoprotein
LDL 5 low density lipoprotein
Lp(a) 5 lipoprotein(a)
L-NMMA 5 N-monomethyl L-arginine
NO 5 nitric oxide
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are reported as mean value 6 SE; all other values as mean
value 6 SD. Two-sided p values are given throughout the text.
Results
Patient characteristics. Clinical characteristics of the total
study group are given in Table 1. All 57 subjects were
normotensive, and none was taking any specific cardiovascular
medication. No participant had a history of diabetes. The mean
Lp(a) plasma level was 22.30 6 22.69 mg/dl (4.8 6 2.5, 13.0 6
3.0 and 49.2 6 20.3 mg/dl in the lower, middle and upper
tertile, respectively). Age; body mass index; blood pressure;
and total, HDL and LDL cholesterol did not differ among
tertiles (Table 2). Six of the 57 subjects were smokers with a
daily cigarette consumption of 2 to 6 cigarettes/day. Three
smokers were in the lower tertile, one in the middle and two in
the upper tertile; mean cigarette consumption did not differ
among tertiles. None of the 24 female subjects was on a
regimen of oral contraceptives or transdermal estrogen substi-
tution.
Endothelium-dependent vasodilation. Forearm blood flow
before the administration of acetylcholine was 4.11 6 1.44,
4.52 6 1.26 and 4.20 6 0.95 ml/min per 100 ml in the lower,
middle and upper tertile, respectively (p 5 NS). A dose-
dependent increase in blood flow was measured for acetylcho-
line in all tertiles (p , 0.001). No significant differences in
forearm blood flow changes from baseline were noted among
tertiles (Fig. 1).
Endothelium-independent vasodilation. Before adminis-
tration of sodium nitroprusside, forearm blood flow was 5.20 6
1.69, 5.89 6 2.19 and 5.27 6 1.72 ml/min per 100 ml in the
lower, middle and upper tertile, respectively (p 5 NS). A
similar dose-dependent increase in blood flow was measured
for endothelium-independent vasodilation in all tertiles (p ,
0.001). No significant differences in forearm blood flow
changes from baseline were observed among tertiles (Fig. 2).
Basal production and release of nitric oxide (NO). Before
the administration of L-NMMA, forearm blood flow was
Figure 1. Percent change (mean 6 SE) in forearm blood flow (FBF)
during infusion of different doses of acetylcholine (ACH, mg/min) in
subjects classified into tertiles by plasma Lp(a) levels. Open bars 5
lower tertile; shaded bars 5 middle tertile; solid bars 5 upper tertiles.
Figure 2. Percent change (mean 6 SE) in forearm blood flow (FBF)
during infusion of different doses of sodium nitroprusside (SNP,
ng/min) in subjects classified into tertiles by plasma lipoprotein(a)
levels. Open bars 5 lower tertile; shaded bars 5 middle tertile; solid
bars 5 upper tertile.
Table 1. Characteristics of the 57 Study Patients
Mean 6 SD
Age (yr) 36.8 6 14.3
Weight (kg) 72.2 6 10.8
Height (m) 1.73 6 0.08
Body mass index (kg/m2) 23.9 6 3.1
Systolic BP (mm Hg) 122 6 15
Diastolic BP (mm Hg) 78 6 11
Total cholesterol (mg/dl) 237 6 75
LDL cholesterol (mg/dl) 213 6 59
HDL cholesterol (mg/dl) 65 6 20
Triglycerides (mg/dl) 132 6 75
Lp(a) (mg/dl) 22.3 6 22.7
BP 5 blood pressure; HDL 5 high density lipoprotein; LDL 5 low density
lipoprotein; Lp(a) 5 lipoprotein(a).
Table 2. Characteristics of Subjects Classified by Lipoprotein(a)
Plasma Level Tertile*
Lp(a)
Lower Tertile
(n 5 19)
Middle Tertile
(n 5 19)
Upper Tertile
(n 5 19)
Age (yr) 31.8 6 11.4 41.7 6 15.8 36.8 6 14.5
Weight (kg) 73.0 6 11.0 73.0 6 9.0 70.8 6 12.4
Height (m) 1.75 6 0.09 1.73 6 0.09 1.72 6 0.05
Body mass index (kg/m2) 23.7 6 3.3 24.5 6 3.0 23.8 6 3.2
Systolic BP (mm Hg) 123 6 14 124 6 14 122 6 18
Diastolic BP (mm Hg) 78 6 8 77 6 11 77 6 13
Total cholesterol (mg/dl) 224 6 86 256 6 74 230 6 64
LDL cholesterol (mg/dl) 141 6 80 167 6 71 135 6 56
HDL cholesterol (mg/dl) 60 6 15 61 6 15 74 6 26
Triglycerides (mg/dl) 113 6 78 144 6 79 105 6 56
*Analysis of variance showed no significant differences among tertiles for any
of the variables shown. Data are presented as mean value 6 SD. Lower Tertile 5
lipoprotein(a) [Lp(a)] ,10 mg/dl (average: 4.8 6 2.5); Middle Tertile 5 Lp(a)
$10 and #20 mg/dl (average: 13.0 6 3.0); Upper Tertile 5 Lp(a) .20 mg/dl
(average: 49.2 6 20.3). Abbreviations as in Table 1.
361JACC Vol. 31, No. 2 SCHLAICH ET AL.
February 1998:359–65 Lp(a) AND BASAL NO RELEASE
5.02 6 1.32, 5.85 6 2.08 and 5.81 6 1.37 ml/min per 100 ml in
the lower, middle and upper tertile, respectively (p 5 NS).
Percent changes from baseline after the administration of
different doses of L-NMMA are shown in Figure 3. L-NMMA
caused a decrease in forearm blood flow in a dose-dependent
manner in all tertiles (p , 0.001). However, changes in
forearm blood flow in response to L-NMMA differed among
tertiles (ANOVA, p , 0.02). Subsequent tests revealed signif-
icant differences among tertiles for 2 and 4 mmol/min of
L-NMMA, with the greatest vasoconstriction occurring in the
tertile with the highest Lp(a) concentration (each p , 0.05).
These differences were significant even after total cholesterol,
HDL cholesterol, triglycerides and LDL cholesterol were
taken into account (p , 0.05). In accordance, Lp(a) concen-
trations correlated significantly with changes in forearm blood
flow after the administration of 4 mmol/min of L-NMMA (r 5
20.38, p , 0.006) (Fig. 4) and tended to be related to values
after 2 mmol/min of L-NMMA (r 5 20.26, p 5 0.06) and 1
mmol/min of L-NMMA (r 5 20.26, p 5 0.06).
By multiple stepwise regression analysis, plasma Lp(a) level
was the strongest determinant of forearm blood flow changes
in response to L-NMMA (4 mmol/min of L-NMMA: R2 5 0.33,
beta 5 20.44, p , 0.01). Total cholesterol, HDL cholesterol or
LDL cholesterol did not emerge as independent determinants.
Thus, Lp(a) appeared to be the most important determinant of
basal production and release of NO in our study group.
Analysis for LDL cholesterol. In a subsequent analysis we
tested the interaction between LDL cholesterol and forearm
blood flow changes in response to acetylcholine by classifying
subjects into groups with an LDL cholesterol concentration
,160 or $160 mg/dl. Significant differences were observed
between groups with low and high LDL cholesterol levels for
all acetylcholine doses tested (3 mg/min, 146.9 6 145.7% vs.
51.9 6 42.4% [p , 0.001]; 12 mg/min, 265.9 6 228.9% vs.
164.7 6 133.9% [p , 0.05]; 24 mg/min, 391.1 6 273.6%
Figure 3. Percent change (mean 6 SE) in forearm blood flow (FBF)
during infusion of different doses of L-NMMA (mmol/min) in subjects
classified into tertiles by plasma Lp(a) levels. Open bars 5 lower
tertile; shaded bars 5 middle tertile; solid bars 5 upper tertile.
Figure 4. Relation between Lp(a) concentration and changes in
forearm blood flow (FBF) after infusion of L-NMMA (4 mmol/min)
(p , 0.02 between groups and p , 0.05 for the upper tertile versus the
middle and the lower tertile by ANOVA).
Figure 5. Percent change (mean 6 SE) in forearm blood flow (FBF)
during infusion of different doses of acetylcholine (ACH) in subjects
with low (open bars) and high (solid bars) LDL cholesterol.
Figure 6. Percent change (mean 6 SE) in forearm blood flow (FBF)
during infusion of different doses of L-NMMA in subjects with low
(open bars) and high (solid bars) LDL cholesterol.
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vs. 234.7 6 175.9% [p , 0.02]; 48 mg/min, 586.0 6 363.3% vs.
344.8 6 211.5% [p , 0.003]) (Fig. 5) but not for L-NMMA (1
mmol/min, 2.1 6 8.2% vs. 0.26 6 11.1% [p 5 NS]; 2 mmol/min,
212.7 6 10.5% vs. 214.9 6 20.8% [p 5 NS]; 4 mmol/min,
220.0 6 11.0% vs. 221.7 6 13.7% [p 5 NS]) (Fig. 6).
Discussion
An elevated Lp(a) plasma concentration has been identi-
fied (1–5,12) as an independent risk factor for coronary heart
disease, stroke and peripheral atherosclerosis. In the current
study we tested the hypothesis that the increased cardiovascu-
lar risk associated with elevated Lp(a) plasma levels might be
mediated by an impairment of endothelial function. In our
study, endothelium-dependent vasodilation as tested by the
administration of different doses of acetylcholine was not
impaired. Therefore, NO-mediated vasodilator response did
not seem to be impaired by Lp(a) in our study cohort.
Furthermore, endothelium-independent vasodilation as as-
sessed by infusion of sodium nitroprusside was similar in the
groups with low, medium and high Lp(a) concentrations.
Therefore, the response to exogenous NO administration did
not seem to be impaired by Lp(a) in our middle-aged subjects.
Our most intriguing finding is the significant difference
observed in response to the inhibition of basal NO production
and release by L-NMMA, with an increased vasoconstriction in
subjects with relatively high levels of Lp(a). This difference
remained significant even after other factors, known to influ-
ence endothelium-dependent vasodilation, such as total cho-
lesterol, LDL and HDL cholesterol, were taken into account.
By multiple stepwise regression analysis, plasma Lp(a) level
emerged as the strongest determinant of vasoconstrictive re-
sponse in the forearm vasculature to administration of
L-NMMA.
Interpretation of vasoreactive response. Previous studies
(25,26) have demonstrated that the highest dose of L-NMMA
used in our study is at the top of the dose-response curve.
These data suggest that we used a complete blockade of basal
NO synthesis in our setting. Sudhir et al. (27), who found an
increased vasoconstrictor response to L-NMMA in women
taking supplementary estrogen interpreted these data as a hint
for an increased basal NO synthesis, as estrogen has been
found (28) to stimulate constitutive NO synthase in cell culture
experiments. In addition, the response to L-NMMA was found
(29) to be greater in young, healthy premenopausal women
taking oral contraceptives than in those not taking them.
Therefore, the increased vasoconstrictor response to the ad-
ministration of L-NMMA observed in our subjects appears to
reflect an increased basal NO production and release by high
Lp(a) levels.
Cardiovascular risk factors and endothelial function. In
early atherosclerosis, impaired endothelial function is the first
indicator of vascular structural changes (6). Some cardiovas-
cular risk factors such as arterial hypertension (6) and hyper-
cholesterolemia (20,21) have been shown to impair stimulated
endothelium-dependent vasodilation. This observation was
confirmed in our study for the cardiovascular risk factor
hypercholesterolemia, but not for elevated Lp(a). In subjects
exposed to the cardiovascular risk factors of smoking (30) or
diabetes mellitus (26), basal NO synthesis has been found to be
impaired. Calver et al. (26) found a reduced response to
blockade of NO synthesis with L-NMMA in the forearm
vasculature in patients with insulin-dependent diabetes, indi-
cating a diminished contribution of NO to overall forearm
vascular tone. The observation of a similarly reduced response
to sodium nitroprusside in the diabetic patients was inter-
preted as a reduced sensitivity of the vascular smooth muscle
to NO. In our study, basal NO production and release were not
impaired in subjects with the cardiovascular risk factor ele-
vated Lp(a). In contrast, elevated Lp(a) levels were associated
with increased basal NO production and release. Furthermore,
the vasodilator response to sodium nitroprusside was not
impaired by elevated Lp(a) concentrations in our study group.
Therefore, in our study, neither a diminished sensitivity of the
vascular smooth muscle to NO nor a decreased stimulated or
basal NO synthesis as found for other cardiovascular risk
factors appeared to account for Lp(a)-induced atherosclerotic
effects.
Lp(a) and endothelial function. In a study by Tsurumi et
al. (31), elevated Lp(a) levels were associated with impaired
endothelium-dependent vasodilation in the coronary arteries.
Sorensen et al. (32) found that flow-mediated dilation was
inversely related to Lp(a) in the superficial femoral artery in
hypercholesterolemic children. However, because basal pro-
duction and release of NO were not assessed in these studies,
it is not known whether basal NO synthesis was altered in those
patients. Furthermore, there are important differences among
the study cohorts in age, cardiovascular risk factor profile and
the vascular bed under examination. Subjects in the study by
Tsurumi et al. had a mean age of 58 6 9 years compared with
37 6 14 years in our patients, and increasing age is known to
impair endothelial function. Whereas we included only sub-
jects with no clinical evidence of atherosclerosis, the patients in
the study by Tsurumi et al. had been referred for cardiac
catheterizaton and suffered from chest pain. In addition, a
large number of patients presented with cardiovascular risk
factors such as smoking and hypertension. Sorensen et al. (32)
found an inverse relation between Lp(a) and flow-mediated
dilation only in children with hypercholesterolemia but not in
control subjects. Whether this effect was due to elevated Lp(a)
levels or to the coexisting hypercholesterolemia cannot be
answered from these data. In our study subjects with high
Lp(a) levels, we found an increased basal NO synthesis that
was independent of total, HDL and LDL cholesterol. With
respect to these important differences and the fact that basal
synthesis of NO was not assessed in the studies of Tsurumi and
Sorensen, the mechanisms underlying these conflicting results
cannot be conclusively clarified.
Possible pathophysiologic mechanisms. The regulation of
vascular tone is based on a balance between vasodilator and
vasoconstrictive components. It is well established that NO is
an important, although not the only, mediator of long-term
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control of vasodilator tone (33). Because stimulated NO
production and release were not impaired in our subjects with
high Lp(a) levels, and basal NO synthesis was even increased,
Lp(a)—in contrast to other cardiovascular risk factors—
appears to exert its atherogenetic properties by mechanisms
other than impairment of NO synthesis. An increased basal
production and release of NO might represent a compensatory
mechanism to counteract Lp(a)-induced atherosclerotic and
vasoconstrictive effects, which are not yet understood. Physio-
logically released NO inhibitors might be increased by Lp(a)
with the consequence of an enhanced NO synthesis to maintain
vascular tone (33). Lp(a) might interact with intracellular NO
storages, whose importance was shown by Davisson et al. (34)
when they found progressively smaller vasodilator responses to
successive injections of acetylcholine and bradykinin after NO
synthase inhibition in rats. Alternatively, Lp(a) could be in-
volved in the stimulation of local production of vasoconstric-
tors such as endothelin (35). To date, no data are available on
the interaction between Lp(a) and NO storage capacities or
other factors mentioned favoring one of these mechanisms to
explain the Lp(a)-induced increase in basal NO synthesis. The
increased contribution of NO to overall vascular tone as
observed in our subjects with high Lp(a) might predispose
these subjects to an increased vulnerability to other factors
interfering with NO synthesis, such as smoking (17,30), diabe-
tes mellitus (26), hypertension (6) or hypercholesterolemia
(20,21).
Conclusions. In conclusion, our results argue against the
hypothesis that Lp(a) acts on the endothelium through a well
defined NO pathway in the manner described for LDL choles-
terol, arterial hypertension, diabetes mellitus or smoking.
Neither stimulated NO synthesis nor basal NO production and
release seemed to be impaired by elevated Lp(a) concentra-
tions. Our study was not designed to demonstrate the under-
lying pathogenetic mechanisms of why production and release
of NO in patients with high Lp(a) are increased. However,
identification of the pathophysiologic mechanisms underlying
the increased basal NO synthesis in subjects with elevated
Lp(a) might provide new insights into the regulatory process of
endothelium-dependent vasorelaxation and should be pursued
in further studies.
We thank Anja Friedrich, Research Nurse, for outstanding help in performing
this study and collecting the data.
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